Core Viewpoint - A lawsuit has been filed against BioAge Labs, Inc. and its senior executives for potential violations of federal securities laws related to their initial public offering and subsequent disclosures regarding their clinical trials [1][2]. Company Overview - BioAge Labs, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic products for metabolic diseases, particularly obesity [3]. Legal Context - The lawsuit claims violations under Sections 11 and 15 of the Securities Act of 1933, specifically concerning the registration statement for BioAge's IPO on September 26, 2024 [2]. - The case is currently pending in the U.S. District Court for the Northern District of California, titled Soto v. BioAge Labs, Inc., et al., No. 25-cv-196 [2]. Clinical Trial Details - BioAge's IPO documents highlighted the ongoing STRIDES Phase 2 trial of its lead product candidate, azelaprag, in combination with GLP-1R agonists for enhanced weight loss, with expectations for topline results in Q3 2025 [4]. - The company claimed collaboration with Eli Lilly and Company for the trial's design and execution, asserting no safety concerns at the time [4]. Trial Discontinuation - The STRIDES Phase 2 trial was discontinued due to safety concerns after subjects exhibited elevated liver enzyme levels, indicating potential organ damage [5]. - BioAge announced the discontinuation on December 6, 2024, leading to a significant stock price decline of over 76%, from $20.09 to $4.65 per share within three days [6].
BIOA FINAL DEADLINE: BioAge Labs Investors are Encouraged to Contact BFA Law before the Expiration of Today's Class Action Deadline